Seeking Alpha

BioLineRx receives NOA for anti-gluten toxicity polymer

  • The USPTO issues a Notice of Allowance to BioLineRx (NASDAQ:BLRX) covering the use of its polymer, BL-7010, for the prevention or decreasing of gluten's deleterious side effects on the gastrointestinal mucosa. The patent, when issued, will be in effect until 2026.
  • BL-7010 is a non-absorbable orally available polymer intended for the treatment of celiac disease. It has a high affinity for gliadins, the immunogenic proteins in gluten that cause celiac disease. BL-7010 masks gliadins from enzymatic degradation which prevents the formation of immunogenic peptides that trigger the immune response. The immune response to gluten is thereby significantly reduced. BL-7010 is excreted via the bowel and not absorbed into the blood stream.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs